On Mar. 24, 2020, Resverlogix announced a Mar. 23, 2020 bioRxiv publication that has shown apabetalone to inhibit specialized proteins ﾖ called bromodomain and extraterminal domain (BET) proteins ﾖ from interacting with a SARS-CoV-2 viral protein, with potential for limiting viral reproduction in human cells.

The article titled: ﾓA SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposingﾔ by Gordon et al, identified BRD2/4 as a binding partner of viral protein E. Apabetalone was shown to disrupt this interaction.